study evidence revealed that treatment with low-dose aspirin had no worthwhile benefit in patients with AD and increased the risk of serious bleeds (1)
the AD2000 study shows that, for patients with AD and no clinically evident cardiovascular disease, transient ischaemic attack, or stroke, 2 years of treatment with low-dose aspirin
8% patients on aspirin and 1% patients in the control group had bleeds that led to admission to hospital (relative risk=4·4, 95% CI 1·5–12·8; p=0·007); 2% patients in the aspirin group had fatal cerebral bleeds.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.